AISLING CAPITAL
Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
AISLING CAPITAL
Industry:
Biotechnology Health Care Venture Capital
Founded:
2000-01-01
Status:
Active
Contact:
(212) 651-6379
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default WordPress AJAX Libraries API Typekit Mimecast Starfield Technologies Sucuri Cloudproxy
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-14 | Dren Bio | Aisling Capital investment in Series B - Dren Bio | 65 M USD |
| 2021-11-03 | Antios Therapeutics | Aisling Capital investment in Series B - Antios Therapeutics | 75 M USD |
| 2021-09-23 | Garuda Therapeutics | Aisling Capital investment in Series A - Garuda Therapeutics | 72 M USD |
| 2021-07-15 | Wugen | Aisling Capital investment in Series B - Wugen | 172 M USD |
| 2021-04-12 | Antios Therapeutics | Aisling Capital investment in Series B - Antios Therapeutics | 96 M USD |
| 2021-03-12 | Monte Rosa Therapeutics | Aisling Capital investment in Series C - Monte Rosa Therapeutics | 95 M USD |
| 2021-01-06 | Biomea Fusion | Aisling Capital investment in Series A - Biomea Fusion | 56 M USD |
| 2020-12-09 | Reneo Pharmaceuticals | Aisling Capital investment in Series B - Reneo Pharmaceuticals | 95 M USD |
| 2020-11-18 | Elevation Oncology | Aisling Capital investment in Series B - Elevation Oncology | 65 M USD |
| 2020-10-06 | Talaris Therapeutics | Aisling Capital investment in Series B - Talaris Therapeutics | 115 M USD |